Case 1: A 73-year-old man with good past health presented to the emergency department with a few days’ history of involuntary low-amplitude unpredictable movements of his left arms and legs.
Case 2: An 84-year-old man with a few years’ history of type 2 diabetes mellitus was admitted with 2 days’ history of involuntary flinging movements of his right arm and leg.
A 38-year-old right-handed man had had epilepsy since 2 months of age. There was no relevant family history. Perinatal history was unremarkable. No other risk factors such as central nervous system infection or cerebral trauma were identified. Developmental history did not show major delay. His epilepsy was uncontrolled despite trying valproate, carbamazepine, clobazam, levetiracetam, oxcarbamazepine and perampanel.
The syndrome of sensory neuronopathy and detection of anti-Hu antibody in 2010 were very strong indications of the presence of a malignant tumour. In a series of 200 patients positive for anti-Hu, 83.5 percent were found to have cancer, and 90 percent of the cancer cases were small-cell lung cancer.
A 55-year-old man presented with almost one year history of heat intolerance, mild palpitation and significant weight loss. Free T3 and T4 were elevated with normal TSH. Patient had suboptimal response to carbimazole therapy.
A contraceptive vaginal system (Annovera) releasing a combination of segesterone acetate and ethinyl estradiol (SA/EE) effectively inhibits ovulation up to a year even at low systemic levels of SA, reports a review study presented at ENDO 2019.
Men with advanced prostate cancer who have pre-existing cardiovascular disease (CVD) may have an elevated mortality risk after treatment with abiraterone acetate compared with men who do not have CVD, according to a study presented at AACR 2019.